Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1264-1805 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health Related Quality of Life (HRQoL) data. This registry will include the entirety of children treated with Norditropin® for short stature due to NS over the inclusion period. The decision to initiate treatment with commercially available Norditropin® is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Incident patients | Children initiated Norditropin® upon their inclusion in the study but independently from the decision to participate in this study |
| |
| Prevalent patients - finished growth upon inclusion | Children were already treated with Norditropin® before their inclusion in the study and finished their growth upon their inclusion. Data collected retrospectively from medical records |
| |
| Prevalent patients - not finished growth upon inclusion | Children were already treated with Norditropin® before their inclusion in the study and did not finish their growth upon inclusion. Data collected both retrospectively and prospectively |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Norditropin | Drug | Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in height standard deviation score | Measured in standard deviation scores (SDS) ranging from -10 to +10 | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of adverse drug reactions (ADR) | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Number of serious adverse drug reactions (SADR) | Count of events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The registry will include children treated with Norditropin® for short stature due to NS.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency dept. 2834 | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Universitaire D'Angers-2 | Angers | 49033 | France | |||
| Ap-Hp-Hopital de Bicetre-2 |
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009634 | Noonan Syndrome |
| ID | Term |
|---|---|
| D019465 | Craniofacial Abnormalities |
| D009139 | Musculoskeletal Abnormalities |
| D009140 | Musculoskeletal Diseases |
| D006330 | Heart Defects, Congenital |
Not provided
Not provided
| ID | Term |
|---|---|
| D019382 | Human Growth Hormone |
| ID | Term |
|---|---|
| D013006 | Growth Hormone |
| D010908 | Pituitary Hormones, Anterior |
| D010907 | Pituitary Hormones |
| D036361 | Peptide Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Number of serious adverse events (SAE) | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Number of adverse events (AE) | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Education | Number of participants is measured under the categorical variables - standard education, education with assistance and educational measures | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| School level | Number of participants is measured under the variables - preschool, elementary school, secondary school and high school | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Educational measures | Number of participants is measured under the categorical variables - physiotherapy, psychomotricity, occupational therapy and speech therapy | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Tanner stage | Measured as units on scale. 3 sub-scales used - Pubic hair scale, Female breast development scale and Male external genitalia scale. Tanner stages range from Stage 1 to 5 with Tanner Stage 1 corresponding to the pre-pubertal form and Tanner Stage 5 corresponding to the final adult form | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in pulse rate | Measured in beats per minute | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in diastolic blood pressure | Measured in millimeters of Mercury (mm Hg) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in systolic blood pressure | Measured in mm Hg | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in corrected QT-interval (Electrocardiogram) | Measured in millisecond (msec) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in echocardiogram parameters (mm) | Change in Left ventricular interventricular septal maximum thickness in diastole and Left ventricular end diastolic diameter is measured in millimeter (mm) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in echocardiogram parameters (%) | Change in Left Ventricular Fractional Shortening (LVFS) and Left Ventricular Ejection Fraction (LVEF) is measured in percentage (%) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in echocardiogram parameters (cm/s) | Change in Diastolic function (Ea and Aa) measured in centimeters per second (cm/s) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in complete blood count (CBC) (g/dL) | Change in Haemoglobin (Hb) measured in grams per deciLiter (g/dL) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in CBC (G/L) | Change in white blood cells, lymphocytes, monocytes and platelets measured in grams per liter (G/L) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in Insulin-like growth factor 1 (IGF-1) level (ng/ml) | Measured in nanograms per milliliter (ng/ml) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in IGF-1 level (SDS) | Measured in SDS | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in Haemoglobin A1c (HbA1c) level | Measured in % | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting insulin level | Measured in milligrams per deciliter (mg/dL) or milli-international units per litre (mUI/L) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting blood glucose level | Measured in mg/dL or g/L or millimoles per litre (mmol/L) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting total cholesterol | Measured in mg/dl or g/L or mmol/L | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting triglycerides | Measured in mg/dL or g/L or mmol/L | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting high-density lipoproteins (HDL) cholesterol | Measured in mg/dL or g/L or mmol/L | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting low-density lipoproteins (LDL) cholesterol | Measured in mg/dL or g/L or mmol/L | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in fasting total cholesterol/HDL ratio | Ratio of fasting total cholesterol and HDL | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in inhibin B | Measured in picograms per milliliter (pg/mL) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in Anti-Müllerian Hormone (AMH) | Measured in milligrams per milliliter (mg/mL) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in Luteinizing Hormone (LH) (female from 8 years old and male from 9 years old) | Measured in mg/mL | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in Follicle-Stimulating Hormone (FSH) (female from 8 years old and male from 9 years old) | Measured in International units per litre (UI/L) or mUI/mL | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in oestradiol (female from 8 years old and male from 9 years old) | Measured in pg/mL | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in testosterone (female from 8 years old and male from 9 years old) | Measured in ng/mL | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in dose of Norditropin® treatment | Measured in milligram per kilogram per day (mg/kg/day) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Frequency of injections of Norditropin® treatment per week | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Number of modifications (change in dosage/ temporary stop) | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Reasons for treatment modifications | Measured in number of participants under categorical variable - safety (occurrence of ARs or AEs), growth too fast, growth too slow, patient's or parents/LAR choice; and other | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Duration of temporary stop | Measured in months | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Total duration of Norditropin® treatment | Measured in years | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Total cumulative dose of Norditropin® treatment | Measured in mg/kg | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Type and number of concomitant treatments | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Type and number of concomitant treatments linked to an adverse event | Count of events | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in weight | Measured in SDS | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in body mass index (BMI) | Measured in kilogram per square metre (kg/m^2) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in bone age | Measured in year | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in height velocity (cm/year) | Measured in cm/year | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in height velocity (SDS/year) | Measured in SDS/year | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Type and number of NS comorbidities | Number of participants measured under categorical variables - Cardiac defects including pulmonary valve stenosis and hypertrophic cardiomyopathy, Orthopaedic issues (pectus, scoliosis) and Anorchia in males | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Change in Health-Related Quality of Life (HRQoL) score (PedsQL) | PedsQL score used to assess the HRQoL, ranges from 1 to 100 (higher scores indicate better HRQoL) | From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years) |
| Le Kremlin-Bicêtre |
| 94275 |
| France |
| Hopital Des Enfants-2 | Toulouse | 31059 | France |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D006728 |
| Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |